Health/Disease Strategy

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

Find out about the latest treatment and drug pipeline developments

Find out what’s in the drug pipeline for autoimmune disease.

Mental health advocate Patrick J. Kennedy talks to Managed Healthcare Executive about reform, mental health equity, and how payers can help integrate care in mental health.

We have a path to ending the HIV epidemic in the United States, but it requires health plans and healthcare purchasers to take a more active role in getting us there.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

Telephonic and personalized diabetes self-education programs which fit into patient’s busy lives will make a greater impact than in-person classes only.

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Leader of the YMCA’s Diabetes Prevention Program explains how it is improving diabetes care.

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.

Here are some of the latest precision medicine approaches being used by managed care organizations, health systems and academic medical centers across the U.S.

After carefully considering its promise and consulting with experts, Independence Blue Cross this year became the first major insurer to provide coverage for certain members who are seeking access to whole genome sequencing.

The Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.

Drugs will be provided to health plan members on clinical trials free of charge.

Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?

Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.

Two reports highlight areas of elderly care that healthcare systems and health plans should avoid.

Several recent studies explore how weight loss surgery impacts diabetes patient care.

How one health system and one health plan are fighting the obesity epidemic

Obesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?

Obesity affects almost 38% of U.S. adults, according to the CDC’s National Health and Nutrition Examination Survey. Here’s how plans and providers can create positive change.

Losing weight requires dramatic behavioral and lifestyle changes. Here’s how physicians can get patients on board.